May 21, 2024
Diabetic Kidney Disease

The Diabetic Kidney Disease Market is Estimated to Witness High Growth Owing to Advancements in Treatment Drugs

Diabetic kidney disease, also known as diabetic nephropathy, is a chronic condition caused due to long-term poorly controlled diabetes. It mainly develops as a complication of type 1 and 2 diabetes and is a leading cause of kidney failure. The increasing prevalence of diabetes globally is driving demand for treatment options such as antihypertensive medications, ACE inhibitors, Angiotensin II receptor blockers, and SGLT2 inhibitors which help slow down the progression of kidney damage.

The Global Diabetic Kidney Disease Market is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in The Diabetic Kidney Disease Market are AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, Vertex Pharmaceuticals Incorporated. The companies are focusing on developing new drugs and combination therapies for better treatment outcomes.

The key opportunities in the market include growing awareness about diabetes management, increasing healthcare expenditure, and launch of new treatment guidelines. Several clinical trials are being conducted to evaluate new molecules for Diabetic Kidney Disease. Advancements in target specific drug therapies such as SGLT2 inhibitors are expected to drive significant growth in the market.

Market drivers:

The growing elderly population with diabetes and rising obesity and unhealthy lifestyles increasing the risk of diabetes are some of the key factors driving the growth of the Diabetic Kidney Disease market. According to estimates, nearly 1 in 3 Americans is expected to develop some form of chronic kidney disease due to diabetes by 2030. Stringent regulatory guidelines regarding the labelling and marketing of anti-diabetic drugs will also promote the development of safer and more effective treatment options.

Current challenges in the Diabetic Kidney Disease Market
The Diabetic Kidney Disease Market faces several challenges currently. One of the major challenges is lack of awareness about disease management. Many patients suffering from diabetes are unaware about risks of kidney damage if diabetes is not well managed. Early diagnosis and intervention is critical to slow progression of kidney disease but achieving mass awareness remains a hurdle. Rising healthcare costs pose another challenge as treatment of diabetic kidney disease requires long term management through multiple drugs and dialysis. Affordability of treatment is a concern in developing regions. Thirdly, lack of novel therapies also acts as a barrier as current treatment options only manage symptoms but do not provide cure. New drug discovery and clinical research in this area needs more investments.

SWOT Analysis
Strength: Growing prevalence of diabetes resulting in rise of diabetic kidney disease patient pool. Solid clinical research on newer therapeutic targets.
Weakness: Lack of cure and dependence on symptomatic treatment options. High costs of treatment and dialysis poses affordability issues.
Opportunity: Untapped growth potential in developing regions due to increasing diabetes burden. Scope for novel drugs targeting kidney protection in early disease stages.
Threats: Stringent regulatory processes delay market entry of new therapies. Patent expiries of major drugs resulting in price erosion.

Geographical Regions
In terms of value, North America region currently holds the major share in the global diabetic kidney disease market owing to large patient pool, advanced healthcare infrastructure and high healthcare spending. The United States alone accounts for over 50% market share. Rising medical costs have urged regulatory reforms but the region will continue to dominate in the forecast period as well.

Asia Pacific region represents the fastest growing market for diabetic kidney disease currently and potential to maintain growth momentum during next decade. Factors such as rapid economic growth, improving access to healthcare and rising prevalence of diabetes due to lifestyle changes are driving the market in Asia Pacific countries. China and India with huge populations are key emerging markets.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it